FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileAppili Therapeutics Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
APLIF
Appili Therapeutics Inc. Stock AnalysisComprehensive stock analysis for Appili Therapeutics Inc. (APLIF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisAPLIF
APLIF
Appili Therapeutics Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
APLIF
  1. Home
  2. Stocks
  3. Appili Therapeutics Inc.

Appili Therapeutics Inc.

🇺🇸APLIF•OTC

Appili Therapeutics Inc.

🇺🇸APLIF•OTC
Market cap
$1.70M

Your view on APLIF

Mkt Cap
$1.70M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Appili Therapeutics Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Donald D. Cilla Jr. Pharmd
Headquarters
#21-1344 Summer Street, Halifax, NS, CA
Industry
Biotechnology
Sector
Healthcare
CEO
Donald D. Cilla Jr. Pharmd
Headquarters
#21-1344 Summer Street, Halifax, NS, CA
Description

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada.

Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis.

The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Appili Therapeutics Inc.. Starting points for Appili Therapeutics Inc.: EPS -$0.04, beta 0.07 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Appili Therapeutics Inc.. Appili Therapeutics Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Appili Therapeutics Inc.. Trailing twelve-month EPS for Appili Therapeutics Inc. stands at -$0.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
More →

Earnings per share estimates

Per shareThis quarterDec 2019Next quarterDec 2020
Average estimate−CAD 0.04−CAD 0.07
Lowest estimate−CAD 0.04−CAD 0.07
Highest estimate−CAD 0.04−CAD 0.07
Number of analysts11
A year ago——
Growth vs a year ago——

Revenue estimates

TotalThis quarterDec 2019Next quarterDec 2020
Average estimateCAD 101132.00CAD 15033.00
Lowest estimateCAD 101132.00CAD 15033.00
Highest estimateCAD 101132.00CAD 15033.00
Number of analysts11
A year ago——
Growth vs a year ago——

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Appili Therapeutics Inc.. Appili Therapeutics Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold APLIF19 companies
Compare APLIF with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
AAGHAmerica Great HealthHealthcareBiotechnology$2.1M
AGNPFAlgernon Pharmaceuticals Inc.HealthcareBiotechnology$1.1M
HESGHealth Sciences Group, Inc.HealthcareBiotechnology$187,094
IBOGFUniversal Ibogaine Inc.HealthcareBiotechnology$2.2M
IBXXFImagion Biosystems LimitedHealthcareMedical - Diagnostics & Research$2.2M
NMLSFRestart Life Sciences Corp.HealthcareBiotechnology$3.5M
RGBPRegen BioPharma, Inc.HealthcareBiotechnology$37,866
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
NAMSNewAmsterdam Pharma Company N.V.HealthcareNASDAQ$2.4B
NAMSWNewAmsterdam Pharma Company N.V.HealthcareNASDAQ$2.3B
NAUTNautilus Biotechnology, Inc.HealthcareNASDAQ$309.5M
NAVBQNavidea Biopharmaceuticals, Inc.HealthcareOTC$100
NBIONascent Biotech, Inc.HealthcareOTC$51,665
NBIXNeurocrine Biosciences, Inc.HealthcareNASDAQ$16.5B
NBPNovaBridge BiosciencesHealthcareNASDAQ$104.1M
NBRVFNabriva Therapeutics plcHealthcareOTC$646
NBTXNanobiotix S.A.HealthcareNASDAQ$1.4B
NC6.AXNanollose LimitedHealthcareASX—
NCELNewcelX Ltd.HealthcareNASDAQ$1.2M
NCNANuCana plcHealthcareNASDAQ$5.1M
Open Comparable Analysis
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Appili Therapeutics Inc.. Coverage tracks Appili Therapeutics Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Appili Therapeutics Inc.

APLIF AnalysisWeak
Past
1
Growth
1
Health
0
Profit
1
Value
0